A Phase I, Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Administered HS-10360 in Healthy Subjects.
Latest Information Update: 05 Jun 2023
At a glance
- Drugs HS-10360 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 10 Aug 2021 New trial record